CYTOKINETICS, INCORPORATED

Public Equity (NASDAQ)BiopharmaceuticalCardiovascularPublic

📍 South San Francisco, CA, USA

StreetZero Signal 63

Be the first to signal interest

About CYTOKINETICS, INCORPORATED

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on muscle biology with over 25 years of scientific innovation. It advances a pipeline of potential medicines for cardiac muscle dysfunction. Its approved product MYQORZO (aficamten) treats adults with symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China.

LATEST FUNDINGRule 144

$1.4M

Announced 2026-10-13

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for CYTOKINETICS, INCORPORATED.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED—

HQSouth San Francisco, CA, USA

Industry

Public Equity (NASDAQ)

Tags

BiopharmaceuticalCardiovascularPublicNASDAQ

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Announced $1.4M Rule 144 private placement.
Proposed $650M public common stock offering in 2026.
Priced upsized offering of common stock raising ~$700M.
MYQORZO (aficamten) approved in multiple regions for oHCM.

Ask StreetZero about CYTOKINETICS, INCORPORATED

Put our AI to work on this deal.

What is CYTOKINETICS, INCORPORATED's value proposition?Who are CYTOKINETICS, INCORPORATED's competitors?Why does this raise matter?Summarize CYTOKINETICS, INCORPORATED for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Palo Alto Networks Inc

StoneX Group Inc.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account